BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 285.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,600 shares of the biotechnology company’s stock after buying an additional 68,589 shares during the period. Acadian Asset Management LLC’s holdings in BioMarin Pharmaceutical were worth $5,083,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC purchased a new stake in BioMarin Pharmaceutical during the 2nd quarter worth about $25,000. Rise Advisors LLC purchased a new position in shares of BioMarin Pharmaceutical during the first quarter worth about $30,000. Brooklyn Investment Group grew its position in BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 540 shares during the last quarter. Hantz Financial Services Inc. lifted its position in BioMarin Pharmaceutical by 480.2% in the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares during the period. Finally, Banque Transatlantique SA purchased a new position in BioMarin Pharmaceutical in the first quarter worth $71,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 2.0%

BioMarin Pharmaceutical stock opened at $54.22 on Friday. BioMarin Pharmaceutical Inc. has a 52 week low of $50.76 and a 52 week high of $73.51. The firm has a market capitalization of $10.42 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. The company has a 50 day moving average price of $53.87 and a 200 day moving average price of $56.63.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). The business had revenue of $776.13 million for the quarter, compared to analysts’ expectations of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BMRN. Wolfe Research reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 28th. Truist Financial lowered their price target on BioMarin Pharmaceutical from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, October 28th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Finally, HC Wainwright reduced their target price on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating on the stock in a report on Monday, October 27th. Sixteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.